In situ indirect fluorescent antibody: a new specific test to detect ongoing chagasic infections

A M Levy1, E Boainain, J K Kloetzel

  • 1Instituto Dante Pazzanese de Cardiologia, São Paulo University, Brasil.

Insights

A new in situ immunofluorescence assay (ISIFA) effectively monitors Chagas disease treatment. This sensitive diagnostic tool distinguishes between successfully treated patients and those requiring further intervention, showing high accuracy.

Area of Science:

  • Medical Parasitology
  • Immunodiagnostics
  • Tropical Diseases

Background:

  • Chagas disease diagnosis and treatment monitoring remain challenging.
  • Existing diagnostic methods have limitations in sensitivity and specificity for evaluating treatment success.
  • A need exists for a reliable assay to assess treatment outcomes in chronically infected patients.

Purpose of the Study:

  • To develop and validate an in situ immunofluorescence assay (ISIFA) for selecting and monitoring treatment in Chagas disease patients.
  • To compare the efficacy of ISIFA with established diagnostic techniques.

Main Methods:

  • Development of ISIFA using flash-fixed trypomastigotes as antigen.
  • Comparison of ISIFA results with complement-mediated lysis (CoML), membrane immunofluorescence (MbIFA), standard immunofluorescence assay (IFA), and xenodiagnosis (XENO).
  • Evaluation of ISIFA sensitivity and specificity in patient cohorts with varying treatment statuses and in individuals with other infections.

Main Results:

  • ISIFA successfully differentiated between untreated, treatment-failure, and successfully treated Chagasic patients (GMTs 180, 160, and 25, respectively).
  • High sensitivity (98.6%) was observed with titers ≥80, detecting active infections missed by other methods.
  • Excellent specificity (98%) was demonstrated against sera from other infections, including leishmaniasis and autoimmune diseases.

Conclusions:

  • ISIFA is a highly sensitive and specific diagnostic tool for monitoring Chagas disease treatment.
  • The assay can accurately identify patients who have responded successfully to therapy.
  • ISIFA offers a valuable advancement for clinical management and follow-up of Chagas disease.

Related Concept Videos

FISH - Fluorescent In-situ Hybridization02:07

FISH - Fluorescent In-situ Hybridization

Fluorescence in situ hybridization, or FISH, was developed in the early 1980s and has quickly become one of the most widely used techniques in cytogenetics. Labeled probes are used to bind complementary DNA or RNA sequences on a chromosome or in a region within a cell. Earlier, the probes could only be obtained by cloning or reverse transcription of a DNA template. Currently, the probe oligonucleotides can be synthesized synthetically. Additionally, with the advancement of optical techniques,...
Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.
Immunofluorescence Microscopy01:12

Immunofluorescence Microscopy

A fluorescence microscope uses fluorescent chromophores called fluorochromes, which can absorb energy from a light source and then emit this energy as visible light. Fluorochromes include naturally fluorescent substances (such as chlorophylls) and fluorescent stains that are added to the specimen to create contrast. Dyes such as Texas red and FITC are examples of fluorochromes. Other examples include the nucleic acid dyes 4’,6’-diamidino-2-phenylindole (DAPI), and acridine orange.
The...